Conservative treatment of early stage ovarian cancer: Oncological and fertility outcomes

I. Zapardiel, M. D. Diestro, G. Aletti

Research output: Contribution to journalArticlepeer-review


Background Ovarian cancer may appear in young women during their reproductive age. As a result of late childbearing nowadays, fertility preservation has become a major issue in young women with gynecological cancer. The aim of this review is to update the current knowledge on conservative treatment and fertility preservation of women affected of early stage epithelial ovarian cancer. Material and methods A web-based search in Medline and CancerLit databases on conservative treatment for early stage ovarian cancer has been carried out. All relevant information has been collected and analyzed. Results Less than 40% of ovarian cancers are diagnosed at early stages. Conservative treatment may be considered in young patients with a relapse rate that ranges from 9% to 29%, and a 5-year survival ranging from 83% to 100%. Recurrences in the controlateral ovary has been reported to be less than 5%, with most of these patients being alive after savage treatments. Moreover, it has been reported good fertility outcomes after conservative treatment with a successful conception rate that ranges from 60% to 100%, with an abortion rate under 30% in all series reported. Conclusions Conservative treatment for early epithelial ovarian cancers could be a safe option for women younger than 40 years who wish to preserve their childbearing potential. We need a strict case selection such as FIGO stage I grade 1 and 2, although grade 3 cases could be considered.

Original languageEnglish
Pages (from-to)387-393
Number of pages7
JournalEuropean Journal of Surgical Oncology
Issue number4
Publication statusPublished - 2014


  • Clinical management
  • Conservative treatment
  • Early stage
  • Fertility sparing surgery
  • Ovarian cancer

ASJC Scopus subject areas

  • Oncology
  • Surgery


Dive into the research topics of 'Conservative treatment of early stage ovarian cancer: Oncological and fertility outcomes'. Together they form a unique fingerprint.

Cite this